Viatris (Mylan) is lined up to copy 3 of the blockbuster drugs on this tracker, which earned $36.5B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Viatris (Mylan)'s stage | 2025 brand sales |
|---|---|---|---|---|---|
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | Approved Jan 2022; now discontinued | $2.7B |
| Eliquis | Bristol Myers Squibb / Pfizer | Generic | 2028 | FDA-approved, Dec 2019 | $14.4B |
| Ozempic | Novo Nordisk | Generic | 2032 | Settled, terms confidential | ≈$19.3B |
Company facts: SEC company tickers. Each drug page lists sources for these entries. Brand sales show the size of the market, not Viatris (Mylan)'s share of it.